Department of Molecular Medicine, Sapporo Medical University, Chuo-ku, Sapporo, Japan.
Angiogenesis. 2009;12(3):243-9. doi: 10.1007/s10456-009-9144-6. Epub 2009 Mar 26.
Sendai virus vector is emerging as a promising vector for gene therapy, and angiopoietin-1 (Ang-1) has been reported to improve the blood flow recovery in the ischemic limb or heart. In this study, we constructed a human Ang-1-expressing Sendai viral vector (SeVhAng-1) and injected it into the ischemic limb of rats. We found that SeVhAng-1 improved the blood flow recovery and increased the capillary density of the ischemic limb, compared with the controls. We also found that SeVhAng-1 increased p-Akt during the early period of limb ischemia, and decreased apoptosis in ischemic limb. It suggests that SeVhAng-1 may serve as a potential therapeutic tool in ischemic limb disease.
仙台病毒载体作为一种有前途的基因治疗载体正在兴起,血管生成素-1(Ang-1)已被报道可改善缺血肢体或心脏的血流恢复。在这项研究中,我们构建了表达人 Ang-1 的仙台病毒载体(SeVhAng-1),并将其注射到大鼠的缺血肢体中。我们发现,与对照组相比,SeVhAng-1 改善了血流恢复并增加了缺血肢体的毛细血管密度。我们还发现,在肢体缺血的早期,SeVhAng-1 增加了 p-Akt,减少了缺血肢体中的细胞凋亡。这表明 SeVhAng-1 可能成为缺血性肢体疾病的一种潜在治疗工具。